Abstract
In a series of substituted piperazines, phenyl methyl piperazine (A1390) was found to have potent adrenergic blocking activity in animals. It blocks and reverses the pressor effects of epinephrine. It blocks, but does not reverse, the pressor effects of nor-epinephrine, ephedrine, desoxyephedrine and hydroxyamphetamine, but does not block naphthyl-methyl-imidazoline.
A1390 blocks the pressor response to anoxia, tilting, and carotid sinus occlusion. It also blocks the nictitating membrane response to superior cervical nerve stimulation.
A1390 does not prevent epinephrine tachycardia nor reduce epinephrine toxicity in mice. It has little atropine-like action, and is only weakly antihistaminic. It does not have a direct vasodilator action in the perfused rabbit ear or heart. The local anesthetic potency of this compound is comparable to that of procaine. Its antihypertensive action in rats has a duration much longer than the adrenolytic activity. A small rise in threshold for vagal inhibition of the heart occurred only after large doses of A1390.
Acute and chronic toxicity data indicate that its therapeutic ratio is relatively favorable.
Examination of the properties of congeners did not reveal consistent or definitive structure-activity relationships.
Footnotes
- Received August 22, 1953.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
BLOCKING EFFECTS OF A SERIES OF SUBSTITUTED PIPERAZINES
